Deep Dive

GLP-1 Data Explorer, Q3 2026: The Whole-Product Race

With leading injectables at 20% to 28% weight loss, GLP-1 competition is shifting to oral convenience, tolerability, persistence, lean mass, and comorbidity labels. This is the interactive data behind our GLP-1 and Metabolic Intelligence Report, Q3 2026, as of August 2026. Click any chart, card, or row to see what sits behind it.

Deep Dive

GLP-1 Data Explorer, Q3 2026: The Whole-Product Race

With leading injectables at 20% to 28% weight loss, GLP-1 competition is shifting to oral convenience, tolerability, persistence, lean mass, and comorbidity labels. This is the interactive data behind our GLP-1 and Metabolic Intelligence Report, Q3 2026, as of August 2026. Click any chart, card, or row to see what sits behind it.

This is the interactive data explorer for ourGLP-1 and Metabolic Intelligence Report, Q3 2026.

GLP-1 Data Explorer, Q3 2026: The Whole-Product Race

No GatingGLP-1 Data Explorer, Q3 2026: The Whole-Product Race
Download

Run this analysis on your own question

Every finding here came from Sleuth’s knowledge base. Bring your own asset, target, or indication, and Sleuth builds the analysis for you.